Pathogenesis of sarcopenia in liver cirrhosis and current status of its diagnosis and treatment
10.3969/j.issn.1001-5256.2020.04.041
- VernacularTitle:肝硬化肌肉减少症的发病机制及诊治现状
- Author:
Jia LIU
1
;
Hua HUANG
Author Information
1. Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
- Publication Type:Research Article
- Keywords:
liver cirrhosis;
sarcopenia;
diagnosis;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(4):895-899
- CountryChina
- Language:Chinese
-
Abstract:
Sarcopenia is an important manifestation of malnutrition in liver cirrhosis and has become a non-negligible complication of patients with liver cirrhosis. It is closely associated with patients’ quality of life, length of hospital stay, incidence rate of complications, and mortality rate and has great impact on the prognosis of liver transplantation. Therefore, early diagnosis and intervention are of great importance in improving the prognosis of patients with liver cirrhosis. However, no consensus has been reached on the diagnostic criteria for sarcopenia in China and foreign countries. In recent years, in-depth studies of muscle molecular regulation mechanism, muscle growth-related hormones, hyperammonemia-mediated signaling pathways, and intestinal flora have gradually revealed the pathogenesis of sarcopenia. Proper nutrition intervention, reasonable exercise, ammonia reduction therapy, hormone supplementation, and molecular targeted therapy may improve muscle mass in patients with liver cirrhosis, which are important hotspots for future research. This article summarizes the recent research on sarcopenia in liver cirrhosis and elaborates on its epidemiological features, pathogenesis, diagnosis, and treatment.
